Semaglutide Results at 1 Month: What to Realistically Expect

You just started semaglutide. You scrolled through Reddit, Instagram, and TikTok and saw people showing dramatic results after a month. You are either excited because you think you will see the same, or disappointed because you are already one week in and seeing nothing yet.

Here is the honest picture: the first month is not the time for dramatic results. If you are following the label schedule, you are on a starting dose that is meant for adjustment, not for long-term use. Here is what is actually happening.

Every trial figure on this page comes from studies of the manufacturer’s brand-name semaglutide (Wegovy). None of these trials studied compounded semaglutide, and their results do not apply to compounded products.

What the starting dose actually is

Wegovy injection starts at 0.25mg once weekly for weeks 1-4. The dose then goes up every 4 weeks: 0.5mg (weeks 5-8), 1mg (weeks 9-12), and 1.7mg (weeks 13-16). From week 17, the maintenance dose for weight reduction in adults is 1.7mg or 2.4mg weekly (2.4mg recommended), and adults who tolerate 2.4mg for at least 4 weeks may go up to 7.2mg if more weight reduction is needed^[3].

Wegovy tablets start at 1.5mg once daily for 30 days, then step up every 30 days to a 25mg daily maintenance dose^[3].

The label lists 0.25mg (injection) and 1.5mg (tablets) as starting doses, separate from the maintenance doses. It says to follow the dose increases to reduce the risk of stomach and bowel side effects^[3]. The goal of weeks 1-4 is to let your body adjust so you can tolerate higher doses later.

That is the plan on the label. It can feel slow, and that is expected.

What the STEP-1 trial shows for early results

The STEP 1 trial (published in the New England Journal of Medicine in 2021) enrolled 1,961 adults with obesity, or overweight plus at least one weight-related condition, who did not have diabetes. Participants took semaglutide 2.4mg or placebo once weekly, plus a lifestyle program, for 68 weeks^[1].

STEP 1 reported its main results at week 68, not at week 4. At 68 weeks, average weight change was -14.9% with semaglutide (about 15.3kg) and -2.4% with placebo (about 2.6kg)^[1]. The published abstract does not report a month-one figure, so be wary of anyone who quotes a specific number of pounds for the first month.

The earliest published time point that fits this page comes from STEP 4. In its 20-week run-in, 902 adults without diabetes took semaglutide, including 16 weeks of dose increases. The 803 (89%) who reached the 2.4mg dose had lost an average of 10.6% of their body weight by week 20^[2]. Everyone in the run-in took semaglutide (there was no placebo group yet), and the figure leaves out the people who did not reach 2.4mg.

Look at the timeline: in both trials, the results built over many months, not the first 4 weeks. Results vary, and trial results describe study participants, not a prediction for you.

What you might actually notice in month one

Some people at the starting dose notice changes. Some notice nothing yet. Both are common.

Possible early signs (weeks 1-4):

• Subtle shift in appetite for certain foods
• Feeling full a bit sooner
• Quieter “food noise” (the constant mental chatter about food that many people describe)
• Nausea as your body adjusts
• Changes in digestion, such as diarrhea or constipation

Not yet typical (weeks 1-4):

• Strong appetite suppression (this usually comes, if at all, at higher doses)
• Large weight loss (the starting dose is for adjustment)
• Visible before-and-after changes
• Sustained energy changes

If you notice nothing at the starting dose, do not panic. It does not tell you how you will respond at higher doses. Many people notice more as the dose increases.

Why social media month-one results are almost always misleading

Four reasons the one-month results you see online do not represent what is happening to you:

1. They may not be on the label schedule

On the Wegovy injection label, the dose goes up every 4 weeks, so by the end of month one you are still at 0.25mg^[3]. Someone posting “one month results” may have started at a higher dose, had prior experience with the medication, or been on a schedule their prescriber set differently. Their month one is not your month one.

2. Selection and timing bias

The person who is one month in and seeing nothing does not post. The person with a striking result does. Your feed is not showing you the typical experience. The FTC’s Endorsement Guides (16 CFR Part 255) say that when an ad shows a consumer’s results, people are likely to read it as what most users will generally achieve, so an advertiser that cannot back that up has to clearly disclose the results people can generally expect^[6]. The FTC’s 2024 rule on consumer reviews and testimonials (16 CFR Part 465) also bans fake testimonials^[7]. A single post is not evidence of a typical result.

3. Compounding medication variability

Some programs prescribe compounded semaglutide, and their dose schedules or starting doses may not match the Wegovy label. Compounded semaglutide is not FDA-approved, and the FDA does not review it for safety, effectiveness, or quality^[5]. If a post is about a compounded product, its timeline and its strength may not be comparable to the brand-name medicine or to your own schedule.

4. Visual perception tricks

Angles, lighting, water weight, and clothing changes can create the look of weight loss before much fat loss has happened. Early drops in water weight can look significant in before-and-after photos. That is real weight change, but it is not fat loss.

The realistic first-month progression

Month 1 is getting used to the medication and building a routine. Here is how the label schedule lays out the early weeks:

The first month sets up the dose increases that follow. Most of the weight change reported in the trials came later.

Why the starting dose is low

If your prescriber started you at the label’s starting dose with a gradual schedule, here is the reasoning:

Side effects: The Wegovy label says to follow the dose escalation schedule to reduce the risk of stomach and bowel side effects, and to consider delaying an increase for 4 weeks if a dose is not tolerated^[3]. In STEP 1, nausea and diarrhea were the most common side effects and were typically temporary and mild to moderate^[1].

Staying on treatment: Side effects are a common reason people stop. In STEP 1, 4.5% of participants on semaglutide stopped treatment because of stomach and bowel side effects, compared with 0.8% on placebo^[1]. In STEP 4, 11% of people in the run-in did not reach the 2.4mg dose^[2].

Long-term habits: The label pairs the medication with a reduced-calorie diet and increased physical activity^[3]. Building those habits takes time.

If you are impatient, that is human. Ask your prescriber before changing your schedule.

What the full timeline actually shows

Putting the label and the trials together^[1][2][3]:

• Weeks 1-4: Starting dose (0.25mg injection or 1.5mg tablets). Weight change, if any, is usually small.
• Weeks 5-16: The injection dose goes up every 4 weeks (0.5mg, 1mg, 1.7mg). Many people notice more appetite change during this stretch.
• Week 17 onward: Maintenance dose (1.7mg or 2.4mg injection). In STEP 4, people who completed the 20-week run-in had lost an average of 10.6% by week 20.
• Week 20 to week 68: In STEP 4, people who kept taking semaglutide lost a further 7.9% on average, while those switched to placebo regained 6.9%. In STEP 1, average weight loss at week 68 was 14.9% with semaglutide and 2.4% with placebo.

These are averages from brand-name semaglutide trials. Individual results varied widely, and stopping the medication often led to regain.

Side effects and safety

Benefits are only half the picture. The Wegovy label^[3] lists:

• Boxed warning: in rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether Wegovy causes these tumors, including medullary thyroid carcinoma (MTC), in humans.
• Who should not use it: people with a personal or family history of MTC or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and people with a known serious allergy to semaglutide or the product’s ingredients.
• Most common side effects: nausea, diarrhea, vomiting, constipation, abdominal pain, dysesthesia (an abnormal skin sensation), headache, fatigue, indigestion, dizziness, bloating, burping, low blood sugar in people with type 2 diabetes, gas, stomach flu, reflux, and hair loss.
• Warnings: acute pancreatitis, gallbladder disease, low blood sugar when used with insulin or sulfonylureas, kidney injury from dehydration, severe stomach and bowel reactions, serious allergic reactions, diabetic retinopathy complications in people with type 2 diabetes, heart rate increase, and the risk of inhaling stomach contents during anesthesia or deep sedation.
• Pregnancy: when used for weight reduction, stop when pregnancy is recognized.

If side effects are severe or do not ease, contact your prescriber.

For compounded semaglutide specifically

Transformation Health is an independent guide. It does not prescribe, sell, or compound medication. If a program you are considering prescribes compounded semaglutide:

• Compounded semaglutide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed^[5].
• It is not the same as brand-name Wegovy and may differ in formulation, purity, and potency.
• The trial results on this page come from brand-name semaglutide and cannot be assumed to apply to compounded products.
• Ask the program which dose schedule it uses, how it compares with the label schedule, which pharmacy prepares the medication, and how to reach the prescriber if side effects are hard to tolerate.

FDA determined that the semaglutide injection shortage was resolved on February 21, 2025, and the periods during which FDA did not intend to act against compounders over shortage-dependent conditions have ended (FDA page current as of 04/01/2026)^[4]. Prices vary by program and dose, so compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms.

Transformation Health does not accept payment from providers. How we make money.

What to actually focus on in month one

Stop measuring against social media. Instead, focus on these month-one goals:

The habit: Can you take your medication on schedule (the same day each week for the injection, every morning for tablets)? If yes, that is progress.

Tolerability: Are you managing side effects well enough to continue? If you are struggling, tell your prescriber. The label allows dose increases to be delayed.

Nutrition: Are you eating enough protein even if your appetite is lower? If you are concerned about losing muscle, ask your prescriber or a dietitian about protein and strength training.

Hydration: Drink water consistently. Severe vomiting or diarrhea can lead to dehydration, which the label links to kidney problems^[3].

Patience: In the trials, weight loss built over many months. Accepting that early on can make the first weeks less discouraging.

Next steps

You are one month in, or about to start. Here is what to do:

1. Treat month one as the adjustment phase and set your expectations accordingly.
2. Follow your dose schedule. Do not rush, and ask your prescriber before restarting after missed doses; the label says escalation restarts at a lower dose if 2 or more weekly injections in a row are missed^[3].
3. Eat enough protein even as your appetite decreases.
4. Check in with your prescriber around week 4 about how you are tolerating the dose before it goes up.
5. Set a check-in with yourself at month 3 (week 12) to look at the trend with your prescriber.

Any before and after is a story of many months, not one. The people online showing dramatic results at month one may be on a different schedule, or they may be outliers.

If month one feels like nothing is happening, you are in good company. That is common at the starting dose.

Citations

[1] Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” N Engl J Med. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/ (STEP 1: 1,961 adults; -14.9% vs -2.4% at 68 weeks; gastrointestinal events typically transient and mild to moderate; 4.5% vs 0.8% discontinued for gastrointestinal events.)

[2] Rubino D, Abrahamsson N, Davies M, et al. “Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.” JAMA. 2021;325(14):1414-1425. https://pubmed.ncbi.nlm.nih.gov/33755728/ (902 in run-in; 803 [89.0%] reached 2.4 mg; 10.6% during the 20-week run-in; -7.9% continued vs +6.9% placebo from week 20 to 68.)

[3] U.S. Food and Drug Administration. WEGOVY (semaglutide) injection and tablets, prescribing information. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

[4] U.S. Food and Drug Administration. “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize.” Content current as of 04/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize (Accessed 2026-10-16.)

[5] U.S. Food and Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” Content current as of 10/01/2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss (Accessed 2026-10-16.)

[6] Federal Trade Commission. Guides Concerning the Use of Endorsements and Testimonials in Advertising, 16 CFR 255.2(b). https://www.ecfr.gov/current/title-16/chapter-I/subchapter-B/part-255 (Accessed 2026-10-16.)

[7] Federal Trade Commission. Rule on the Use of Consumer Reviews and Testimonials, 16 CFR 465.2. 89 FR 68077, August 22, 2024. https://www.ecfr.gov/current/title-16/chapter-I/subchapter-D/part-465 (Accessed 2026-10-16.)